Communiqués Cytokinetics, Incorporated

Actions

CYTK

US23282W6057

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/06/2024			Varia. 5j.	Varia. 1 janv.
51,75 ^USD	-2,12%		-0,37%	-38,02%

17/06	Un initié de Cytokinetics a vendu des actions pour une valeur de 262 750 $, selon un récent dépôt auprès de la SEC	MT
17/06	Un initié de Cytokinetics a vendu des actions pour une valeur de 1 183 391 $, selon un récent dépôt auprès de la SEC	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants	17/06	AQ
Cytokinetics Incorporated : Regulation FD Presentation Form 8 K	05/06	PU
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/06	AQ
Cytokinetics to Participate in June Investor Conferences	29/05	AQ
Cytokinetics Announces Closing of Public Offering of Common Stock	28/05	AQ
Cytokinetics Announces Pricing of Public Offering of Common Stock	23/05	AQ
Cytokinetics Announces Proposed Public Offering of Common Stock	22/05	AQ
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline	22/05	AQ
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology	17/05	AQ
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024	15/05	AQ
Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress	13/05	AQ
Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine	13/05	AQ
Cytokinetics: Q1 Earnings Snapshot	08/05	AQ
Cytokinetics Reports First Quarter 2024 Financial Results	08/05	AQ
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy	08/05	AQ
Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586	08/05	AQ
Cytokinetics to Hold Annual Meeting of Stockholders	07/05	AQ
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/05	AQ
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress	29/04	AQ
Cytokinetics to Announce First Quarter Results on May 8, 2024	24/04	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Cytokinetics, Incorporated

Actions

CYTK

US23282W6057

Communiqués

Filtres